Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Zealand Pharma Share Buy-Back Program
Business share buy-back

Zealand Pharma Share Buy-Back Program

Analysis based on 52 articles · First reported May 26, 2026 · Last updated Jul 13, 2026

Sentiment
30
Attention
4
Articles
52
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The share buy-back program by Zealand Pharma is generally viewed positively by the market as it can signal confidence from the company's management and potentially boost earnings per share, leading to increased investor interest. The increase in share capital by Zealand Pharma, while part of the overall program, could dilute existing shares if not offset by buy-backs, but in this context, it's part of a broader capital management strategy.

biotechnology pharmaceuticals
Event Summary

Zealand Pharma A/S, a biotechnology company, is conducting a share buy-back program initiated on May 7, 2026, and set to conclude by October 31, 2026. The program allows for repurchasing shares up to DKK 1.3 billion, with a maximum of 7,152,557 shares. Danske Bank has been appointed as the lead manager, making independent trading decisions. As of week 24 (June 8-12, 2026), Zealand Pharma holds 1,879,482 treasury shares, representing approximately 2.63% of its share capital. The company also increased its share capital by 53,183 new shares on June 8, 2026. The program adheres to EU Market Abuse Regulation and Safe Harbour Regulation.

Key Actions
85 Zealand Pharma initiates share buy-back
40 Zealand Pharma appointed lead manager Danske Bank
Entities Involved
stock
Zealand Pharma
Zealand Pharma is executing a share buy-back program to repurchase its own shares, aiming to return value to shareholders and potentially increase earnings per share. The company has increased its share capital during the program.
Importance 100.0 Sentiment 37.0
stock
Danske Bank
Danske Bank has been appointed as the lead manager for Zealand Pharma's share buy-back program, making independent trading decisions on behalf of the company.
Importance 40.0 Sentiment 0.0
curr
Denmark — Danish krone
The share buy-back program is valued in Danish Krone, with a total consideration of up to DKK 1.3 billion.
Importance 20.0 Sentiment 0.0
exch
Nasdaq Copenhagen
Transactions for Zealand Pharma's share buy-back program are being executed on Nasdaq Copenhagen.
Importance 10.0 Sentiment 0.0
cnt
Denmark
Zealand Pharma is headquartered in Copenhagen, Denmark, and the share buy-back program is conducted under EU regulations.
Importance 5.0 Sentiment 0.0
alliance
European Union
The share buy-back program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, 'MAR') and Commission Delegated Regulation (EU) 2016/1052 (the 'Safe Harbour Regulation').
Importance 5.0 Sentiment 0.0
Relationships
Danske Bank related ↔ Nasdaq Copenhagen
Nasdaq Copenhagen related ↔ Denmark
Denmark related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.